Literature DB >> 16352923

[Intra-arterial chemotherapy for head and neck cancer].

Iwai Tohnai1.   

Abstract

There are historically speaking, three methods of intra-arterial infusion for head and neck cancer. Recently, daily concurrent chemoradiotherapy using new superselective intra-arterial infusion via superficial temporal arterial artery is noted. A catheter with a curved tip is inserted superselectively to the feeding artery of the tumor via the superficial temporal artery. Long-term catheterization is possible in this method. Thirty-five patients with stage III or IV oral cancer were treated. Radiotherapy (total dose:40 Gy/4 weeks) and superselective intra-arterial infusion chemotherapy using DOC (total dose: 60 mg/m2, 15 mg/m2/week) and CDDP total dose: 100 mg/m2, 5 mg/m2/day) were concurrently performed daily, followed by surgery. In 31 patients, intra-arterial infusion was successful(successful rate: 88.6%), and no major complication was observed. The clinical effects were CR in 25 patients(80.6%), and pathological effects of resected tumor after surgery were pathological CR in 28 (90.3%). This method promises to be new strategy of choice for the treatment of head and neck cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16352923

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  Anatomical study of the external carotid artery and its branches for administration of superselective intra-arterial chemotherapy via the superficial temporal artery.

Authors:  Kazumichi Yonenaga; Iwai Tohnai; Kenji Mitsudo; Yoshiyuki Mori; Hideto Saijo; Toshinori Iwai; Yoshiyuki Yonehara; Yoshihide Ota; Kojun Torigoe; Tsuyoshi Takato
Journal:  Int J Clin Oncol       Date:  2011-05-03       Impact factor: 3.402

2.  Analysis of the outcome of concurrent neoadjuvant chemoradiotherapy with S-1 compared to super-selective intra-arterial infusion for oral squamous cell carcinoma.

Authors:  Akihiko Miyawaki; Hiroshi Hijioka; Ryuji Ikeda; Takayuki Ishida; Etsuro Nozoe; Norifumi Nakamura
Journal:  Oncol Lett       Date:  2012-02-13       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.